Literature DB >> 19929564

Matrix metalloproteinase (MMP)-7 in salivary gland cancer.

Heikki Luukkaa1, Pekka Klemi, Pirkko Hirsimäki, Tero Vahlberg, Atte Kivisaari, Veli-Matti Kähäri, Reidar Grénman.   

Abstract

INTRODUCTION: High levels of certain matrix metalloproteinases (MMPs) have been detected in various human cancers. The purpose of this study was to analyze the expression of MMP-7 in salivary gland cancer (SGC) by immunohistochemistry and to associate the results with the clinical data and the 10-year survival of the SGC patients.
MATERIAL AND METHODS: Immunohistochemistry for MMP-7 was performed in a series of 107 paraffin-embedded sections of SGC. The samples represent the entire SGC population in Finland from 1991-1996. Mortality follow-up ended December 31, 2006.
RESULTS: The study population of 107 patients consisted of 47 male and 60 female subjects, ranging in age at the time of diagnosis between 23 and 90 years. The minimum follow-up time was 10.6 years and the maximum 15.9 years. By age-adjusted analysis lower staining intensity was associated with worse overall survival of patients with acinic cell carcinoma (p = 0.047, HR 6.5, 95% Cl 1.0-41.7) and in mucoepidermoid carcinoma (p = 0.010, HR 9.3, 95% CI 1.7-50.0). Low staining intensity was also associated with worse disease-specific survival of patients with acinic cell carcinoma (0-1 vs. 2-3; p = 0.047, HR 13.7, 1.0-200.0). VCI Ki-67 was an important prognostic factor for survival of the entire data set (p < 0.0001, HR 4.7, 95% Cl 2.3-9.8).
CONCLUSIONS: MMP-7 is associated with the prognosis of patients with acinic cell and mucoepidermoid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19929564     DOI: 10.3109/02841860903287197

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

1.  Analysis of matrix metalloproteinase-1 gene polymorphisms and expression in benign and malignant breast tumors.

Authors:  Jing Zhou; Constance Brinckerhoff; Susan Lubert; Kui Yang; Jasmine Saini; Jeffrey Hooke; Richard Mural; Craig Shriver; Stella Somiari
Journal:  Cancer Invest       Date:  2011-11       Impact factor: 2.176

2.  Prognostic value of matrix metalloproteinase-7 expression in patients with non-small cell lung cancer.

Authors:  Yonggang Liang; Shanxian Guo; Qinghua Zhou
Journal:  Tumour Biol       Date:  2013-12-14

3.  Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma.

Authors:  Jing-Hua Zhou; Bin Zhang; Kemp H Kernstine; Li Zhong
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

4.  Matrix Metalloproteinase Responsive, Proximity-activated Polymeric Nanoparticles for siRNA Delivery.

Authors:  Hongmei Li; Shann S Yu; Martina Miteva; Christopher E Nelson; Thomas Werfel; Todd D Giorgio; Craig L Duvall
Journal:  Adv Funct Mater       Date:  2013-06-25       Impact factor: 18.808

5.  Expression of matrix metalloproteinases (MMPs-2, -7, -9, and -26) and tissue inhibitors of metalloproteinases (TIMPs-1 and -2) in pleomorphic adenomas and adenoid cystic carcinomas.

Authors:  Valéria Souza Freitas; Jean Nunes Dos Santos; Pedro Paulo de Andrade Santos; Cassiano Francisco Weege Nonaka; Leão Pereira Pinto; Lélia Batista de Souza
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-10-25       Impact factor: 2.503

6.  Association between promoter polymorphisms of matrix metalloproteinase-1 and risk of gastric cancer.

Authors:  Qisong Peng; Yong Xu
Journal:  Onco Targets Ther       Date:  2015-09-10       Impact factor: 4.147

7.  Amperometric Biosensor of Matrix Metalloproteinase-7 Enhanced by Pd-Functionalized Carbon Nanocomposites.

Authors:  Zheng Wei; Huiqiang Wang; Zhanfang Ma; Hongliang Han
Journal:  Nanoscale Res Lett       Date:  2018-11-22       Impact factor: 4.703

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.